The Technical Analyst
Cyclacel Pharmaceuticals [CYCC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cyclacel Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-29.82% $1.600
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.11 mill |
| EPS: | -26.75 |
| P/E: | -0.0600 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 1.318 mill |
| Avg Daily Volume: | 0.0520 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0600 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0600 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.408 - 1.812 ( +/- 12.55%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-29 | Schwartz Brian | Buy | 12 500 | Common Stock |
| 2024-01-29 | Schwartz Brian | Buy | 12 500 | Stock Option (right to buy) |
| 2023-12-21 | Mcbarron Paul | Buy | 1 886 | Common Stock |
| 2023-12-21 | Mcbarron Paul | Buy | 1 886 | Warrants (right to buy) |
| 2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 3 599 901 | Sell: 12 |
Forecast:
16:00 - $1.605
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.605
Forecast 2: 16:00 - $1.605
Forecast 3: 16:00 - $1.605
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.600 (-29.82% ) |
| Volume | 3.46 mill |
| Avg. Vol. | 0.0520 mill |
| % of Avg. Vol | 6 649.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYCC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Latest Press Releases
2024-04-01 09:15:00 - Press Release
Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 Asco Annual Meeting Highlighting Fadraciclib's Potential As A Precision Medicine For Cancer
- new clinical, pk and pd data from novel cdk2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
2024-03-19 16:05:00 - Press Release
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
– on track to start oral fadraciclib phase 2 proof of concept in 1h 2024 – – expect to report final data from fadraciclib 065-101 dose escalation – – oral plogosertib preclinical data support precision medicine strategy in arid1a- and smarca-mutated cancers – – management to host conference call at 4:30 pm et today – berkeley heights, n.j., march 19, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
2024-03-13 16:05:00 - Press Release
Cyclacel Pharmaceuticals To Release Fourth Quarter And Full Year 2023 Financial Results
Berkeley heights, n.j., march 13, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on tuesday, march 19, 2024. the company will host a conference call at 4:30pm et on the same day.
2024-03-07 09:15:00 - Press Release
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-concept Data For Fadraciclib To Be Presented At The American Association For Cancer Research (aacr) Annual Meeting 2024
Data support ongoing development program of novel cdk2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma data support ongoing development program of novel cdk2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma
2024-03-06 09:15:00 - Press Release
Cyclacel Pharmaceuticals Announces Receipt Of $2.9 Million R&d Tax Credit
Berkeley heights, n.j., march 06, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (r&d) tax credit from hmrc, the tax agency of the united kingdom government. the tax credit is based on r&d costs incurred in the year ended december 31, 2023. the company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures.
Latest News
2024-04-01 09:15:00 - GlobeNewsWire
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -
2024-03-19 18:09:10 - Seeking Alpha
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
2024-03-13 16:05:00 - GlobeNewsWire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day.
2024-02-20 09:15:00 - GlobeNewsWire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.
2024-01-09 09:07:15 - InvestorPlace
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is falling on Tuesday but it's not due to any negative news from the clinical-stage biopharmaceutical company. Instead, shares of CYCC stock are retreating after undergoing a rally on Monday.
2024-01-02 09:15:00 - GlobeNewsWire
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
2023-11-07 09:15:00 - GlobeNewsWire
Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Monday, November 13, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.
2023-10-17 08:16:17 - Zacks Investment Research
New Strong Buy Stocks for October 17th
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
2023-08-03 09:15:00 - GlobeNewsWire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
2023-05-11 19:59:08 - Seeking Alpha
Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu Demir - Ladenburg Thalmann Shubhendu Sen Roy - Brookline Capital Markets Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.